Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity
- PMID: 9435250
- PMCID: PMC18478
- DOI: 10.1073/pnas.95.2.669
Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity
Abstract
Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas, and several other types of human cancers. Because among normal tissues, mesothelin is present only on mesothelial cells, it represents a good target for antibody-mediated delivery of cytotoxic agents. In the present study mice were immunized with an eukaryotic expression vector coding for mesothelin. When high serum antibody titers were obtained, a phage display library was made from the splenic mRNA of these mice. After three rounds of panning on recombinant mesothelin, a single-chain Fv (scFv)-displaying phage was selected that bound specifically to recombinant mesothelin and mesothelin-positive cells. The scFv was used to construct an immunotoxin by genetically fusing it with a truncated mutant of Pseudomonas exotoxin A. The purified immunotoxin binds mesothelin with high affinity (Kd 11 nm), is stable for over 40 hr at 37 degrees C and is very cytotoxic to cells expressing mesothelin. It also produces regressions of tumors expressing mesothelin. This combination of selective cytotoxicity, high activity, and stability makes the immunotoxin a good candidate for development as a therapeutic agent. This work also shows that DNA immunization can be used to isolate and clone antibodies against epitopes present on human proteins in their native conformation.
Figures





Similar articles
-
Isolation of anti-mesothelin antibodies from a phage display library.Mol Immunol. 1997 Jan;34(1):9-20. doi: 10.1016/s0161-5890(97)00011-4. Mol Immunol. 1997. PMID: 9182872
-
Analysis of cloned Fvs from a phage display library indicates that DNA immunization can mimic antibody response generated by cell immunizations.J Immunol Methods. 1999 Dec 10;231(1-2):83-91. doi: 10.1016/s0022-1759(99)00142-8. J Immunol Methods. 1999. PMID: 10648929
-
Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.J Immunother. 2000 Jul-Aug;23(4):473-9. doi: 10.1097/00002371-200007000-00011. J Immunother. 2000. PMID: 10916757
-
Mesothelin: a new target for immunotherapy.Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42. doi: 10.1158/1078-0432.CCR-03-0801. Clin Cancer Res. 2004. PMID: 15217923 Review.
-
Single-chain antibodies in pancreatic cancer.Ann N Y Acad Sci. 1999 Jun 30;880:263-80. doi: 10.1111/j.1749-6632.1999.tb09531.x. Ann N Y Acad Sci. 1999. PMID: 10415872 Review.
Cited by
-
Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus.PLoS One. 2009 Aug 13;4(8):e6625. doi: 10.1371/journal.pone.0006625. PLoS One. 2009. PMID: 19675673 Free PMC article.
-
Preparation of single chain variable fragment of MG(7) mAb by phage display technology.World J Gastroenterol. 2001 Aug;7(4):510-4. doi: 10.3748/wjg.v7.i4.510. World J Gastroenterol. 2001. PMID: 11819819 Free PMC article.
-
Mesothelin as a biomarker for targeted therapy.Biomark Res. 2019 Aug 23;7:18. doi: 10.1186/s40364-019-0169-8. eCollection 2019. Biomark Res. 2019. PMID: 31463062 Free PMC article. Review.
-
Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries.Sci Rep. 2021 Jul 29;11(1):15430. doi: 10.1038/s41598-021-94902-1. Sci Rep. 2021. PMID: 34326410 Free PMC article.
-
scFv antibody: principles and clinical application.Clin Dev Immunol. 2012;2012:980250. doi: 10.1155/2012/980250. Epub 2012 Mar 15. Clin Dev Immunol. 2012. PMID: 22474489 Free PMC article. Review.
References
-
- Press O W, Eary J F, Appelbaum F R, Martin P J, Badger C C, Nelp W B, Glenn S, Butchko G, Fisher D, Porter B. N Eng J Med. 1993;329:1219–1224. - PubMed
-
- Osterborg A, Dyer M J, Bunjes D, Pangalis G A, Bastion Y, Catovsky D, Mellstedt H. J Clin Oncol. 1997;15:1567–1574. - PubMed
-
- Chang K, Pai L H, Batra J K, Pastan I, Willingham M C. Cancer Res. 1992;52:181–186. - PubMed
-
- Chang K, Pai L H, Pass H, Pogrebriak H W, Tsao M-S, Pastan I, Willingham M C. Am J Surg Pathol. 1992;16:259–268. - PubMed
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources